Proteomics International Shares Surge Nearly 20% on Monday. Here's Why.

December 30, 2024 02:23 AM GMT | By Team Kalkine Media
 Proteomics International Shares Surge Nearly 20% on Monday. Here's Why.
Image source: Shutterstock

Highlights

  • Proteomics International Laboratories unveils PromarkerEndo blood test, capable of diagnosing all stages of endometriosis with high accuracy.
  • The test’s breakthrough results, published in Human Reproduction, could revolutionize diagnosis, reducing reliance on invasive laparoscopy.
  • Shares soar 19.8% to 72.5 cents as the company targets a Q2 2025 launch in Australia and explores global licensing opportunities.

Shares of Proteomics International Laboratories Ltd (ASX:PIQ) surged nearly 20% on Monday to 72.5 cents after the company announced a major breakthrough in diagnosing endometriosis. Its PromarkerEndo blood test, detailed in a recent study published in Human Reproduction, demonstrated high accuracy in identifying all stages of the debilitating condition.

Endometriosis affects millions of women worldwide, often causing years of diagnostic delays due to the reliance on invasive laparoscopy. Proteomics International’s innovative test could transform this landscape by offering a simple, non-invasive solution.

The PromarkerEndo Test

The study, conducted in collaboration with the Royal Women’s Hospital and the University of Melbourne, analyzed plasma samples from 805 participants across two independent clinical groups. Using advanced proteomics and statistical modeling, the team developed three diagnostic models.

The standout model, Model 3, achieved near-perfect accuracy in diagnosing severe endometriosis (AUC: 0.997) and showed excellent performance for earlier disease stages (AUCs >0.85 for stages I–III). The test uses a panel of 10 plasma protein biomarkers to screen for the condition, potentially eliminating the need for invasive surgery to confirm diagnosis.

“PromarkerEndo has the potential to revolutionize how we diagnose and manage endometriosis,” said Proteomics International in a statement.

Significant Economic and Social Impact

Endometriosis is a chronic condition that causes severe pain and infertility, costing Australia $9.7 billion annually in healthcare expenses and lost productivity. Current diagnostic methods involve invasive laparoscopy and histopathology, making early diagnosis challenging.

PromarkerEndo’s non-invasive approach could address this gap, enabling early intervention and reducing the physical and financial burden on patients and healthcare systems.

Next Steps and Launch Timeline

Proteomics International is accelerating efforts to bring PromarkerEndo to market, with a target launch in Australia set for Q2 2025. Key developments include:

  • Adapting for Clinical Use: Refining the test’s diagnostic algorithm using a “traffic light” system for improved clinical performance.
  • Global Expansion: Engaging in discussions for licensing in women’s health and fertility markets.
  • Direct-to-Consumer Potential: Leveraging its existing framework for other diagnostic tests, such as PromarkerD for diabetic kidney disease and PromarkerEso for esophageal cancer.
  • Validation Study: Conducting clinical validation with samples from the University of Oxford.
  • Cloud-Based Software Hub: Developing a platform for reporting patient results.

Market Response and Outlook

The breakthrough announcement has boosted investor confidence, propelling Proteomics International’s shares nearly 20% higher.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next